private:aquesys
|
1435644
|
Nov 18th, 2019 12:00AM
|
AqueSys, Inc
|
439
|
6.00
|
Open
|
Medical Device
|
Nov 18th, 2019 03:43PM
|
Nov 18th, 2019 03:43PM
|
AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma by re-envisioning sub-conjunctival outflow with a minimally invasive stent for the reduction of intraocular pressure. Backed by more than a decade of research and recent commercialization in European markets, the safety and efficacy of the company’s proprietary technology supports glaucoma surgeons and patients in the management of intraocular pressure to arrest the progression of vision loss associated with glaucoma. Privately held and headquartered in Southern California, AqueSys is working to change the treatment of glaucoma to benefit patients, physicians and payors around the world through the research, development, manufacturing and commercialization of its minimally invasive glaucoma stents. Additional information about the XEN Gel Stent can be found at www.aquesys.com.
|
Open
|
Ophthalmology, Glaucoma, Medical Devices
|
Open
|
|
|
|
|
|
|
AqueSys
|
|
|
private:aquesys
|
1435644
|
Nov 16th, 2019 12:00AM
|
AqueSys, Inc
|
439
|
6.00
|
Open
|
Medical Device
|
Nov 16th, 2019 03:54PM
|
Nov 16th, 2019 03:54PM
|
AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma by re-envisioning sub-conjunctival outflow with a minimally invasive stent for the reduction of intraocular pressure. Backed by more than a decade of research and recent commercialization in European markets, the safety and efficacy of the company’s proprietary technology supports glaucoma surgeons and patients in the management of intraocular pressure to arrest the progression of vision loss associated with glaucoma. Privately held and headquartered in Southern California, AqueSys is working to change the treatment of glaucoma to benefit patients, physicians and payors around the world through the research, development, manufacturing and commercialization of its minimally invasive glaucoma stents. Additional information about the XEN Gel Stent can be found at www.aquesys.com.
|
Open
|
Ophthalmology, Glaucoma, Medical Devices
|
Open
|
|
|
|
|
|
|
AqueSys
|
|
|
private:aquesys
|
1435644
|
Nov 15th, 2019 12:00AM
|
AqueSys, Inc
|
439
|
6.00
|
Open
|
Medical Device
|
Nov 15th, 2019 12:36PM
|
Nov 15th, 2019 12:36PM
|
AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma by re-envisioning sub-conjunctival outflow with a minimally invasive stent for the reduction of intraocular pressure. Backed by more than a decade of research and recent commercialization in European markets, the safety and efficacy of the company’s proprietary technology supports glaucoma surgeons and patients in the management of intraocular pressure to arrest the progression of vision loss associated with glaucoma. Privately held and headquartered in Southern California, AqueSys is working to change the treatment of glaucoma to benefit patients, physicians and payors around the world through the research, development, manufacturing and commercialization of its minimally invasive glaucoma stents. Additional information about the XEN Gel Stent can be found at www.aquesys.com.
|
Open
|
Ophthalmology, Glaucoma, Medical Devices
|
Open
|
|
|
|
|
|
|
AqueSys
|
|
|
private:aquesys
|
1435644
|
Nov 14th, 2019 12:00AM
|
AqueSys, Inc
|
439
|
6.00
|
Open
|
Medical Device
|
Nov 14th, 2019 05:51PM
|
Nov 14th, 2019 05:51PM
|
AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma by re-envisioning sub-conjunctival outflow with a minimally invasive stent for the reduction of intraocular pressure. Backed by more than a decade of research and recent commercialization in European markets, the safety and efficacy of the company’s proprietary technology supports glaucoma surgeons and patients in the management of intraocular pressure to arrest the progression of vision loss associated with glaucoma. Privately held and headquartered in Southern California, AqueSys is working to change the treatment of glaucoma to benefit patients, physicians and payors around the world through the research, development, manufacturing and commercialization of its minimally invasive glaucoma stents. Additional information about the XEN Gel Stent can be found at www.aquesys.com.
|
Open
|
Ophthalmology, Glaucoma, Medical Devices
|
Open
|
|
|
|
|
|
|
AqueSys
|
|
|
private:aquesys
|
1435644
|
Nov 13th, 2019 12:00AM
|
AqueSys, Inc
|
438
|
6.00
|
Open
|
Medical Device
|
Nov 13th, 2019 01:03PM
|
Nov 13th, 2019 01:03PM
|
AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma by re-envisioning sub-conjunctival outflow with a minimally invasive stent for the reduction of intraocular pressure. Backed by more than a decade of research and recent commercialization in European markets, the safety and efficacy of the company’s proprietary technology supports glaucoma surgeons and patients in the management of intraocular pressure to arrest the progression of vision loss associated with glaucoma. Privately held and headquartered in Southern California, AqueSys is working to change the treatment of glaucoma to benefit patients, physicians and payors around the world through the research, development, manufacturing and commercialization of its minimally invasive glaucoma stents. Additional information about the XEN Gel Stent can be found at www.aquesys.com.
|
Open
|
Ophthalmology, Glaucoma, Medical Devices
|
Open
|
|
|
|
|
|
|
AqueSys
|
|
|
private:aquesys
|
1435644
|
Nov 12th, 2019 12:00AM
|
AqueSys, Inc
|
438
|
6.00
|
Open
|
Medical Device
|
Nov 12th, 2019 02:46PM
|
Nov 12th, 2019 02:46PM
|
AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma by re-envisioning sub-conjunctival outflow with a minimally invasive stent for the reduction of intraocular pressure. Backed by more than a decade of research and recent commercialization in European markets, the safety and efficacy of the company’s proprietary technology supports glaucoma surgeons and patients in the management of intraocular pressure to arrest the progression of vision loss associated with glaucoma. Privately held and headquartered in Southern California, AqueSys is working to change the treatment of glaucoma to benefit patients, physicians and payors around the world through the research, development, manufacturing and commercialization of its minimally invasive glaucoma stents. Additional information about the XEN Gel Stent can be found at www.aquesys.com.
|
Open
|
Ophthalmology, Glaucoma, Medical Devices
|
Open
|
|
|
|
|
|
|
AqueSys
|
|
|
private:aquesys
|
1435644
|
Nov 11th, 2019 12:00AM
|
AqueSys, Inc
|
438
|
6.00
|
Open
|
Medical Device
|
Nov 11th, 2019 02:44PM
|
Nov 11th, 2019 02:44PM
|
AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma by re-envisioning sub-conjunctival outflow with a minimally invasive stent for the reduction of intraocular pressure. Backed by more than a decade of research and recent commercialization in European markets, the safety and efficacy of the company’s proprietary technology supports glaucoma surgeons and patients in the management of intraocular pressure to arrest the progression of vision loss associated with glaucoma. Privately held and headquartered in Southern California, AqueSys is working to change the treatment of glaucoma to benefit patients, physicians and payors around the world through the research, development, manufacturing and commercialization of its minimally invasive glaucoma stents. Additional information about the XEN Gel Stent can be found at www.aquesys.com.
|
Open
|
Ophthalmology, Glaucoma, Medical Devices
|
Open
|
|
|
|
|
|
|
AqueSys
|
|
|
private:aquesys
|
1435644
|
Nov 10th, 2019 12:00AM
|
AqueSys, Inc
|
438
|
6.00
|
Open
|
Medical Device
|
Nov 10th, 2019 05:50PM
|
Nov 10th, 2019 05:50PM
|
AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma by re-envisioning sub-conjunctival outflow with a minimally invasive stent for the reduction of intraocular pressure. Backed by more than a decade of research and recent commercialization in European markets, the safety and efficacy of the company’s proprietary technology supports glaucoma surgeons and patients in the management of intraocular pressure to arrest the progression of vision loss associated with glaucoma. Privately held and headquartered in Southern California, AqueSys is working to change the treatment of glaucoma to benefit patients, physicians and payors around the world through the research, development, manufacturing and commercialization of its minimally invasive glaucoma stents. Additional information about the XEN Gel Stent can be found at www.aquesys.com.
|
Open
|
Ophthalmology, Glaucoma, Medical Devices
|
Open
|
|
|
|
|
|
|
AqueSys
|
|
|
private:aquesys
|
1435644
|
Nov 9th, 2019 12:00AM
|
AqueSys, Inc
|
438
|
6.00
|
Open
|
Medical Device
|
Nov 9th, 2019 05:17PM
|
Nov 9th, 2019 05:17PM
|
AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma by re-envisioning sub-conjunctival outflow with a minimally invasive stent for the reduction of intraocular pressure. Backed by more than a decade of research and recent commercialization in European markets, the safety and efficacy of the company’s proprietary technology supports glaucoma surgeons and patients in the management of intraocular pressure to arrest the progression of vision loss associated with glaucoma. Privately held and headquartered in Southern California, AqueSys is working to change the treatment of glaucoma to benefit patients, physicians and payors around the world through the research, development, manufacturing and commercialization of its minimally invasive glaucoma stents. Additional information about the XEN Gel Stent can be found at www.aquesys.com.
|
Open
|
Ophthalmology, Glaucoma, Medical Devices
|
Open
|
|
|
|
|
|
|
AqueSys
|
|
|
private:aquesys
|
1435644
|
Nov 8th, 2019 12:00AM
|
AqueSys, Inc
|
438
|
6.00
|
Open
|
Medical Device
|
Nov 8th, 2019 02:28PM
|
Nov 8th, 2019 02:28PM
|
AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma by re-envisioning sub-conjunctival outflow with a minimally invasive stent for the reduction of intraocular pressure. Backed by more than a decade of research and recent commercialization in European markets, the safety and efficacy of the company’s proprietary technology supports glaucoma surgeons and patients in the management of intraocular pressure to arrest the progression of vision loss associated with glaucoma. Privately held and headquartered in Southern California, AqueSys is working to change the treatment of glaucoma to benefit patients, physicians and payors around the world through the research, development, manufacturing and commercialization of its minimally invasive glaucoma stents. Additional information about the XEN Gel Stent can be found at www.aquesys.com.
|
Open
|
Ophthalmology, Glaucoma, Medical Devices
|
Open
|
|
|
|
|
|
|
AqueSys
|
|
|